“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
The Centers for Disease Control and Prevention (CDC) has updated its website to state that there could be a link…
21 Nov 2025
Early planning, outsourcing and digitalisation to break down CGT CMC barriers
Since their inception, cell and gene therapies (CGTs) have shown great promise in treating a plethora of challenging diseases. Despite their burgeoning potential, CGT developers face a bumpy road from…
21 Nov 2025
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead autologous cell therapy candidate, ANPD001, for moderate-to-advanced Parkinson’s disease. This…
21 Nov 2025
Alvotech and Advanz announce EC approval for Gobivaz biosimilar
Alvotech and Advanz Pharma have announced the European Commission’s (EC) marketing authorisations for Gobivaz, a biosimilar to Simponi (golimumab), across the European Economic Area (EEA). The authorisations cover Gobivaz in…
20 Nov 2025
CPHI 2025: linker innovation paves the way for a wave of new ADCs
Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door to more stable, selective ADCs with application beyond the class’s…
20 Nov 2025
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
Merck KGaA has signed a drug discovery partnership with Valo Health, becoming the latest big pharma to enlist the services of the tech company to identify the next big therapeutic.…
20 Nov 2025
Moderna to onshore drug product manufacturing to Massachusetts
Moderna is to expand its US manufacturing capabilities with the onshoring of drug product manufacture to its existing Moderna Technology Center (MTC) in Norwood in the state of Massachusetts, in…